肺血管阻力在肺动脉高压患者中的临床应用
Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.
作者信息
Deng Jianying
机构信息
Department of Cardiovascular Surgery, Chongqing Kanghua Zhonglian Cardiovascular Hospital, 168# Haier Road, District of Jiangbei, Chongqing, 400015, China.
出版信息
J Cardiothorac Surg. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4.
Abstract
Pulmonary arterial hypertension is a type of malignant pulmonary vascular disease, which is mainly caused by the increase of pulmonary vascular resistance due to the pathological changes of the pulmonary arteriole itself, which eventually leads to right heart failure and death. As one of the diagnostic indicators of hemodynamics, pulmonary vascular resistance plays an irreplaceable role in the pathophysiology, diagnosis and treatment of pulmonary arterial hypertension. It provides more references for the evaluation of pulmonary arterial hypertension patients. This article summarizes the clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.
摘要
肺动脉高压是一种恶性肺血管疾病，主要由肺小动脉自身病理改变导致肺血管阻力增加引起，最终导致右心衰竭和死亡。作为血流动力学的诊断指标之一，肺血管阻力在肺动脉高压的病理生理学、诊断和治疗中发挥着不可替代的作用。它为评估肺动脉高压患者提供了更多参考依据。本文综述了肺血管阻力在肺动脉高压患者中的临床应用。
相似文献
1
Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.肺血管阻力在肺动脉高压患者中的临床应用
J Cardiothorac Surg. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4.
2
Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?肺动脉高压中的肺血管阻力：关键因素？
Am J Respir Crit Care Med. 2021 Feb 15;203(4):524-525. doi: 10.1164/rccm.202009-3664LE.
3
Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension.为肺动脉高压中肺血管阻力难题增添了重要一环。
Eur Respir J. 2020 Jul 9;56(1). doi: 10.1183/13993003.00962-2020. Print 2020 Jul.
4
Reply to Weatherald : Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?对韦瑟罗尔德的回复：肺动脉高压中的肺血管阻力：关键因素？
Am J Respir Crit Care Med. 2021 Feb 15;203(4):525-526. doi: 10.1164/rccm.202010-3834LE.
5
Pulmonary arterial hypertension: the clinical syndrome.肺动脉高压：临床综合征。
Circ Res. 2014 Jun 20;115(1):115-30. doi: 10.1161/CIRCRESAHA.115.301146.
6
Predictive Value of Pulmonary Arterial Compliance in Systemic Lupus Erythematosus Patients With Pulmonary Arterial Hypertension.肺动脉顺应性对系统性红斑狼疮肺动脉高压患者的预测价值。
Hypertension. 2020 Oct;76(4):1161-1168. doi: 10.1161/HYPERTENSIONAHA.120.15682. Epub 2020 Aug 10.
7
Molecular Pathways in Pulmonary Arterial Hypertension.肺高血压的分子途径。
Int J Mol Sci. 2022 Sep 2;23(17):10001. doi: 10.3390/ijms231710001.
8
[Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].[先天性心脏病相关肺动脉高压患者不同亚型的死亡危险因素及临床特征]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Apr 24;48(4):315-322. doi: 10.3760/cma.j.cn112148-20190628-00364.
9
Chronic thromboembolic and pulmonary arterial hypertension share right ventricular and pulmonary artery CMR features.慢性血栓栓塞性和肺动脉高压具有相似的右心室和肺动脉 CMR 特征。
Pulmonology. 2019 Jul-Aug;25(4):248-251. doi: 10.1016/j.pulmoe.2019.03.002. Epub 2019 May 10.
10
Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压患者肺循环时间常数降低。
Am J Physiol Heart Circ Physiol. 2013 Jul 15;305(2):H259-64. doi: 10.1152/ajpheart.00128.2013. Epub 2013 May 17.
引用本文的文献
1
Factors Influencing Prolonged Hospital Stay in Surgically Treated Children and Adolescents with Left-to-Right Shunt Congenital Heart Disease: Evidence From a Hospital in Southern China.影响接受手术治疗的左向右分流型先天性心脏病儿童及青少年住院时间延长的因素：来自中国南方一家医院的证据
Ther Clin Risk Manag. 2025 Aug 10;21:1237-1247. doi: 10.2147/TCRM.S533273. eCollection 2025.
2
Association of hemodynamic and functional variables with pulmonary vasculopathy in lung transplant recipients living at high altitude: A retrospective study.高海拔地区肺移植受者血流动力学和功能变量与肺血管病变的相关性：一项回顾性研究。
Sci Prog. 2025 Jul-Sep;108(3):368504251367283. doi: 10.1177/00368504251367283. Epub 2025 Aug 17.
3
Omentin-1 as a promising biomarker and therapeutic target in hypertension and heart failure: a comprehensive review.网膜素-1作为高血压和心力衰竭中有前景的生物标志物及治疗靶点：综述
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 24. doi: 10.1007/s00210-025-04008-y.
4
Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells.蛋白酶体抑制剂硼替佐米可抑制肺动脉平滑肌细胞的增殖和迁移。
Kaohsiung J Med Sci. 2024 Jun;40(6):542-552. doi: 10.1002/kjm2.12835. Epub 2024 Apr 29.
5
Echocardiographic features of right ventricle in septic patients with elevated central venous pressure.感染性心内膜炎患者的右心室超声心动图特征。
BMC Anesthesiol. 2024 Apr 4;24(1):128. doi: 10.1186/s12871-024-02515-8.
6
Effects of a Soluble Guanylate Cyclase Stimulator Riociguat on Contractility of Isolated Pulmonary Artery and Hemodynamics of U46619-Induced Pulmonary Hypertension in Dogs.可溶性鸟苷酸环化酶刺激剂利奥西呱对犬离体肺动脉收缩性及U46619诱导的肺动脉高压血流动力学的影响
Vet Sci. 2023 Feb 15;10(2):159. doi: 10.3390/vetsci10020159.
本文引用的文献
1
Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.在肺动脉高压协会注册中心，与甲基苯丙胺相关的特发性肺动脉高压的临床差异和结局。
Ann Am Thorac Soc. 2021 Apr;18(4):613-622. doi: 10.1513/AnnalsATS.202007-774OC.
2
Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry.肺动脉高压协会注册研究的基础结果：与年龄相关的肺高血压血液动力学和功能状态的差异。
J Heart Lung Transplant. 2020 Sep;39(9):945-953. doi: 10.1016/j.healun.2020.05.005. Epub 2020 May 16.
3
Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.左心衰竭的非侵入性预后生物标志物作为肺动脉高压患者生存的预测指标。
Chest. 2020 Jun;157(6):1606-1616. doi: 10.1016/j.chest.2019.12.037. Epub 2020 Jan 25.
4
Culture of pulmonary artery endothelial cells from pulmonary artery catheter balloon tips: considerations for use in pulmonary vascular disease.肺动脉导管球囊尖端的肺动脉内皮细胞培养：在肺血管疾病中的应用考虑。
Eur Respir J. 2020 Mar 20;55(3). doi: 10.1183/13993003.01313-2019. Print 2020 Mar.
5
Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension.系统性硬化症患者的血流动力学表型与生存：新肺动脉高压定义的影响。
Ann Rheum Dis. 2020 Mar;79(3):370-378. doi: 10.1136/annrheumdis-2019-216476. Epub 2019 Dec 9.
6
Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.表型沉默的骨形态发生蛋白受体 2 突变通过增加新生内膜转化的风险使大鼠易患炎症诱导的肺动脉高压。
Circulation. 2019 Oct 22;140(17):1409-1425. doi: 10.1161/CIRCULATIONAHA.119.040629. Epub 2019 Aug 29.
7
Pulmonary Vascular Dynamics.肺血管动力学。
Compr Physiol. 2019 Jun 12;9(3):1081-1100. doi: 10.1002/cphy.c180033.
8
LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation.LRP1 缺失导致血管平滑肌细胞肺动脉高压，PPARγ 激活可逆转该疾病。
Circ Res. 2019 Jun 7;124(12):1778-1785. doi: 10.1161/CIRCRESAHA.119.315088. Epub 2019 Apr 26.
9
Overview: pulmonary vascular function in health and disease.概述：健康与疾病状态下的肺血管功能
J Physiol. 2019 Feb;597(4):973-974. doi: 10.1113/JP277375.
10
Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.肺动脉高压的病理学和病理生物学：现状和研究展望。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01887-2018. Print 2019 Jan.
Zotero 插件